Botulinum Toxin Type A Injections into the Cricopharyngeal Muscle to Treat Upper Esophageal Dysfunction
dc.contributor.author | Greene, Brittani R. | |
dc.date.accessioned | 2018-03-28T18:51:03Z | |
dc.date.accessioned | 2020-06-22T14:35:10Z | |
dc.date.available | 2018-03-28T18:51:03Z | |
dc.date.available | 2020-06-22T14:35:10Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/1069 | |
dc.description | Dysphagia can impact people of all ages because it co-occurs with numerous disorders and health problems. Dysphagia effects over nine million people a year and mainly targets adults over the age of sixty. One cause of dysphagia may be cricopharyngeal dysfunction. This review looks at the use of Botulinum toxin type A (BtxA) injections as a way to relax the cricopharyngeal muscle to help with upper esophageal dysfunction. The literature agreed that botulinum toxin injections are a safe and effective treatment that improves swallowing function for most patients. Patients who did not benefit from BtxA may have had other complications, or a possible diffusion of the BtxA into the surrounding muscle. | en_US |
dc.language.iso | en_US | en_US |
dc.subject | cricopharyngeal | en_US |
dc.subject | botulinum toxin | en_US |
dc.subject | upper esophageal sphincter | en_US |
dc.title | Botulinum Toxin Type A Injections into the Cricopharyngeal Muscle to Treat Upper Esophageal Dysfunction | en_US |
dc.type | Presentation | en_US |
refterms.dateFOA | 2020-06-22T14:35:10Z | |
dc.description.institution | SUNY Plattsburgh |